Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
6.020
+0.045 (+0.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
January 31, 2024
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address...
Via
Benzinga
Exposures
Product Safety
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
January 30, 2024
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.
Via
Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
January 13, 2024
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.
Via
Talk Markets
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
January 24, 2024
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued
January 11, 2024
Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The...
Via
Benzinga
Why Is Clearmind (CMND) Stock Up 40% Today?
January 10, 2024
The jump in Clearmind sent its market cap to $6 million. The study of psychedelic compounds to treat mental illness is growing.
Via
InvestorPlace
MindMed Announces Business Update and Anticipated Milestones for 2024
January 08, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
Via
Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...
Via
Benzinga
Psychedelic Drug Stocks Index Up In December; Down YTD
December 27, 2023
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.
Via
Talk Markets
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
Biden To Decide On Psychedelic Therapy Bill
Via
Benzinga
Psychedelic Drug Stocks Index Declined 1.6% This Week
December 17, 2023
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.
Via
Talk Markets
Topics
ETFs
Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed
December 14, 2023
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no...
Via
Benzinga
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
December 14, 2023
From
Mind Medicine
Via
Business Wire
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
December 11, 2023
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week
December 10, 2023
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.
Via
Talk Markets
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
Defense Dept. Funds Ketamine Study For PTSD Treatment
Via
Benzinga
November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex
December 02, 2023
The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November.
Via
Talk Markets
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
November 23, 2023
Via
Benzinga
GH Research Drags Down Psychedelic Drug Stocks Index By 7%
November 23, 2023
The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week.
Via
Talk Markets
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart
November 11, 2023
Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on...
Via
Talk Markets
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
November 06, 2023
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22%
November 05, 2023
The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances.
Via
Talk Markets
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
November 03, 2023
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers:
Via
Benzinga
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
Mind Medicine
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.